As a result of increasing R&D initiatives in cancer treatment, providers and patients are being wooed with a multitude of choices. However, this has stoked several complexities in treatment options. Both groups are reeling under the possibility of increased progression fee. Besides this, the rising willingness of patients to spend on advanced treatment options, prevalence of unmet needs, and a bulging pipeline of novel drugs are some of the factors which will exert considerable influence on the oncology drugs department.
Through our extensively researched reports, we offer updated perspective on some of the most crucial trends prevailing in this sector. Our observations cover novel treatments, availability of cures, costs incurred in oncology medications and associated drugs, distribution channel, and other related factors, which are crucial to chalk a positive trajectory in the oncology drugs market.
Oncology Drugs Market Research Reports
Mar, 2018 | 171 pages
This report on the prostate cancer therapeutics market examines past and current scenario to present projections at both regional and global level. The global prostate cancer therapeutics market study includes an extensive executive summary, comprising market snapshot that provides information about key segments.
Feb, 2018 | 165 pages
This report on the global basal cell carcinoma treatment market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails.
Jan, 2018 | 226 pages
This report on the global anticancer drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.
Dec, 2017 | 170 pages
The prevention of disease through vaccination is one of the most cost-effective and safe ways. Pneumococcus is one of the leading causes of blood infection, pneumonia, sinusitis, meningitis, and otitis media.
Nov, 2017 | 170 pages
Chronic Myelogenous Leukemia (CML) takes place when the bone marrow starts making too many white blood cells. This may affect red blood cells, white blood cells, and platelets. The first line treatment for CML in chronic phase is being largely treated with targeted drugs such as tyrosine kinase inhibitors (TKIs) nilotinib (Tasigna) and dasatinib (Sprycel).
Nov, 2017 | 170 pages
The global rare hematology market is expected to witness a healthy growth attributed to growing prevalence of blood related disorders. Surge in demand to conduct the diagnosis process at the early phase is expected to impact growth of the global rare hematology market significantly.
Sep, 2017 | 183 pages
The market for oncology biosimilars has just a few players and hence is consolidated in nature. Big shot players in the market are seen forging carefully-considered collaborations to expand their geographical footprints. A case in point is Dr. Reddy’s Laboratories, which entered into an agreement with TR-Pharm to strengthen its presence in the Middle East. According to the deal, TR-Pharm is required to commercialize Dr. Reddy’s three biosimilars in Turkey.
Jan, 2017 | 185 pages
Monoclonal antibodies are a type of biological therapy used in the treatment serious conditions such as cancer, rheumatoid arthritis, Crohn’s diseases, psoriasis, osteoporosis, systemic lupus erythematous, and others. Monoclonal antibody are target specific in action by not affect the other cells of the body thus restores the immune system.
Dec, 2016 | 222 pages
The growing incidences of cancer and a need to treat them is the key driver of the global immunotherapy market. The number of deaths occurring due to cancer is increasing every year and has therefore forced government bodies to take initiatives for the improvement of the health conditions of people, by investing heavily in research and development and enabling innovation and advancements in technology so as to offer improved treatments.
Nov, 2015 | 88 pages
Changes in lifestyle and obesity are some of the key risk factors causing breast cancer. The incidence of the disease is more prevalent in women than in men, and is aggravated by the presence of several co-morbidity factors, with no clear causes. According to Breastcancer.org, a non-profit organization working on the diagnosis, treatment, and management of the disease, about one in eight women in the U.S. is likely to develop invasive breast cancer over the lifetime span.
Jun, 2014 | 100 pages
This report provides the market analysis for various technologies and applications used for the enrichment and detection of circulating tumor cells (CTCs). The stakeholders of this report include companies and research institutes involved in the production of prognosis kits and research and development activities related to circulating tumor cells technologies as well as the new entrants who wish to enter this market.